Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo OKs Bavencio, Maviret, Ibrance and More for Listing on Nov. 22
November 15, 2017
-
ORGANIZATION Deeper Price Cuts Needed for Off-Patent Brands, Scrap 5-Year Grace Period: Chuikyo Payer Rep
November 14, 2017
-
REGULATORY Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products
November 13, 2017
-
BUSINESS Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
November 10, 2017
-
ACADEMIA In Renewed Attempt, Tokushima Univ. Starts IIT for Eisai-Dropped ALS Drug Candidate
November 9, 2017
-
COMMENTARY Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
-
BUSINESS 4 Japan Drug Majors See Half-Year Profit Fall on One-Off Factors, but Global Flagships Thrive
November 7, 2017
-
ORGANIZATION Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says
November 6, 2017
-
REGULATORY Payer Rep Calls on Govt to Promote Use of Formularies at Hospitals to Ensure Use of Cheaper Option: Chuikyo
November 2, 2017
-
REGULATORY PM Abe Watchful of Reward for Me-Too Drugs, CEFP Minutes Reveal
November 1, 2017
-
ORGANIZATION Global Pharma CEOs Prod Japan to Keep Pro-Innovation Policy, Sound Alarm on Proposed PMP Review
October 31, 2017
-
REGULATORY Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too
October 30, 2017
-
REGULATORY CEFP Kicks Off FY2018 Budget Debate with Major Focus on Scope of Off-Year Price Survey, Revision
October 27, 2017
-
REGULATORY Payer Rep Insists CEA-Based Price Hike “Not an Option,” MHLW Wants “Grounds” for That Argument: Chuikyo
October 26, 2017
-
REGULATORY Sanofi’s Dupilumab, Chugai’s PD-L1 Inhibitor and More Up for MHLW Panel Review on Nov. 6
October 25, 2017
-
ACADEMIA Japan’s 1st Constipation Treatment Guidelines Recommend Drugs Acting on Epithelial Function Including Amitiza
October 25, 2017
-
INTERVIEW Takeda Eager to Build Life Science Hub in Shonan, Offer Research Environment Akin to US East Coast: Exec Hirate
October 24, 2017
-
BUSINESS Mitsubishi Tanabe to Focus on US Approval for VLP Seasonal Flu Vaccine; Aims at 100 Billion Yen Sales for Vaccine Business by FY2030
October 24, 2017
-
REGULATORY Japan Introduction of GDP Likely to Begin with Guideline that Calls on Companies to Make “Good Faith Effort”: MHLW Study Group
October 23, 2017
-
BUSINESS LEO Pharma Japan to Set Up Stand-Alone Sales Force in 5 Years, Eyes 100 Reps
October 20, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…